{"name":"ASST Fatebenefratelli Sacco","slug":"asst-fatebenefratelli-sacco","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Hyoscine N-Butil Bromide","genericName":"Hyoscine N-Butil Bromide","slug":"hyoscine-n-butil-bromide","indication":"Other","status":"marketed"},{"name":"low-volume PEG -ascorbic acid","genericName":"low-volume PEG -ascorbic acid","slug":"low-volume-peg-ascorbic-acid","indication":"Other","status":"marketed"},{"name":"Ibuprofen 400 mg","genericName":"Ibuprofen 400 mg","slug":"ibuprofen-400-mg","indication":"Other","status":"marketed"},{"name":"Slit One","genericName":"Slit One","slug":"slit-one","indication":"Phase 3 clinical trials for Slit One are ongoing, but no specific indications have been reported.","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"continue the PI/r-containing HAART.","genericName":"continue the PI/r-containing HAART.","slug":"continue-the-pi-r-containing-haart","indication":"Treatment of HIV-1 infection in combination with other antiretroviral medications","status":"phase_3"},{"name":"RPV + DRV/r","genericName":"RPV + DRV/r","slug":"rpv-drv-r","indication":"HIV-1 infection (treatment-experienced or treatment-naive patients)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Slit One ragweed","genericName":"Slit One ragweed","slug":"slit-one-ragweed","indication":"Ragweed pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"}]}],"pipeline":[{"name":"continue the PI/r-containing HAART.","genericName":"continue the PI/r-containing HAART.","slug":"continue-the-pi-r-containing-haart","phase":"phase_3","mechanism":"Ritonavir is a protease inhibitor used to treat HIV-1 infection by preventing the replication of the virus.","indications":["Treatment of HIV-1 infection in combination with other antiretroviral medications"],"catalyst":""},{"name":"Hyoscine N-Butil Bromide","genericName":"Hyoscine N-Butil Bromide","slug":"hyoscine-n-butil-bromide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Slit One ragweed","genericName":"Slit One ragweed","slug":"slit-one-ragweed","phase":"phase_3","mechanism":"Slit One ragweed is a sublingual immunotherapy that desensitizes the immune system to ragweed allergen through gradual exposure under the tongue.","indications":["Ragweed pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"low-volume PEG -ascorbic acid","genericName":"low-volume PEG -ascorbic acid","slug":"low-volume-peg-ascorbic-acid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ibuprofen 400 mg","genericName":"Ibuprofen 400 mg","slug":"ibuprofen-400-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RPV + DRV/r","genericName":"RPV + DRV/r","slug":"rpv-drv-r","phase":"phase_3","mechanism":"RPV (rilpivirine) and DRV/r (darunavir/ritonavir) are antiretroviral agents that inhibit HIV reverse transcriptase and protease, respectively, blocking viral replication.","indications":["HIV-1 infection (treatment-experienced or treatment-naive patients)"],"catalyst":""},{"name":"Slit One","genericName":"Slit One","slug":"slit-one","phase":"phase_3","mechanism":"Slit One is a drug that works by inhibiting the action of a specific protein.","indications":["Phase 3 clinical trials for Slit One are ongoing, but no specific indications have been reported."],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ncGZWWk9RTzBUOW1GRUN6enhlVVZNQXVQeEJlQTJaY3RxdmswUVJFOUZmbGJ0X2FDZ1NBSWhIR1RqSnFOSVRGWk50UWhmRnpMUkNHLWIyRl90Z09Zbkhz?oc=5","date":"2023-02-12","type":"pipeline","source":"nature.com","summary":"Routine genetic tests could prevent adverse drug reactions - nature.com","headline":"Routine genetic tests could prevent adverse drug reactions","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}